News
Lilly's M&A team strikes again with $2.3bn Ajax takeover
With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.
News
GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio
A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
News
FDA delays decision on Sanofi's subcutaneous Sarclisa
The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.
News
MSD, Eisai report setback in first-line kidney cancer trial
The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.
News
Jazz and Lilly cancer drugs cleared for use by NHS
Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
